ABBV AbbVie Inc

By Matt Grossman

AbbVie Inc.'s AGN-190584 drug, a potential treatment for presbyopia, met the primary and secondary endpoints of a Phase 3 trial, the company said Sunday.

If approved the drug would be the first eye-drop treatment for presbyopia, an inability to focus on near objects, AbbVie said. In the trial, AGN-190584 had a rapid onset of action and vision improved for up to six hours. There was no loss of distance vision, AbbVie said.

The study included 323 participants, half of whom received a placebo. People in the study were evaluated based on how well treatment improved their ability to read lines on an eye chart.

About 128 million Americans have presbyopia, AbbVie said, mostly in middle age or older.

Write to Matt Grossman at matt.grossman@wsj.com

(END) Dow Jones Newswires

July 26, 2021 06:33 ET (10:33 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.